Abstract
Purpose
There are no criteria for administering first- or second-generation anti-androgens (FGA and SGA, respectively) to patients with non-metastatic castration-resistant prostate cancer (nmCRPC). This study aimed to assess the efficacy of alternative FGA therapy in nmCRPC patients and the prognosis of these patients and to identify factors for predicting patients potentially responsive to FGA.
Methods
Data from 63 men with nmCRPC who underwent alternative FGA therapy (bicalutamide, flutamide, or chlormadinone acetate) as first-line therapy after failure of primary androgen-deprivation therapy (PADT) between 2004 and 2017 at Hiroshima University Hospital and affiliated hospitals were retrospectively investigated. The associations of clinicopathological parameters with overall survival (OS) and prostate-specific antigen (PSA) progression-free survival (PFS) of alternative FGA-treated patients were analyzed.
Results
Time to CRPC [p = 0.007, hazard ratio (HR) = 4.77], regional lymph node involvement at the diagnosis of CRPC (p = 0.022, HR = 2.42), and PSA-PFS of alternative FGA therapy ≤ 6 months (p = 0.020, HR = 2.39) were identified as prognostic factors using a multivariate analysis. Additionally, Cox proportional hazard models revealed that PSA nadir value > 1 ng/mL during PADT (p = 0.034, HR = 2.40) and time from starting PADT to PSA nadir ≤ 1 year (p = 0.047, HR = 1.85) were predictive factors for worse PSA-PFS in alternative FGA therapy.
Conclusions
Shorter time to CRPC, regional lymph node involvement, PSA nadir during PADT > 1 ng/mL, and time from starting PADT to PSA nadir ≤ 1 year might suggest the potential benefit of immediate commencement of SGA, compared to FGA administration after nmCRPC diagnosis.
Similar content being viewed by others
References
Akaza H, Usami M, Hinotsu S et al (2004) Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance. Jpn J Clin Oncol 34:329–336
Hussain M, Fizazi K, Saad F et al (2018) Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 378:2465–2474
Smith MR, Saad F, Chowdhury S et al (2018) Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 378:1408–1418
Mizokami A, Kadono Y, Kitagawa Y et al (2017) Therapies for castration-resistant prostate cancer in a new era: the indication of vintage hormonal therapy, chemotherapy and the new medicines. Int J Urol 24:566–572
European Association of Urology (EAU). Oncology Guidelines: Prostate Cancer, 2018. https://uroweb.org/guideline/prostate-cancer/. Accessed 24 May 2019
American Urological Association (AUA). Clinical guidelines: Castration-resistant prostate cancer (2018) https://www.auanet.org/guidelines/prostate-cancer-castration-resistant-guideline. Accessed 24 May 2019
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Prostate Cancer. Version 2. 2019–April 17, 2019. https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed 24 May 2019
Miyake H, Matsushita Y, Watanabe H et al (2019) Comparative assessment of prognostic outcomes between first-generation antiandrogens and novel androgen-receptor-axis-targeted agents in patients with non-metastatic castration-resistant prostate cancer. Int J Clin Oncol. https://doi.org/10.1007/s10147-019-01412-2
Penson DF, Armstrong AJ, Concepcion R et al (2016) Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE Trial. J Clin Oncol 34:2098–2106
Iguchi T, Tamada S, Kato M et al (2019) Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study). BMC Cancer 19:339
Mori K, Kimura T, Ito K et al (2018) Earlier use of androgen receptor-axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancer. Prostate 78:766–772
Suzuki H, Okihara K, Miyake H et al (2008) Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 180:921–927
Fujikawa K, Matsui Y, Fukuzawa S et al (2000) Prostate-specific antigen levels and clinical response to flutamide as the second hormone therapy for hormone-refractory prostate carcinoma. Eur Urol 37:218–222
Miyake H, Hara I, Eto H (2005) Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. BJU Int 96:791–795
Okihara K, Ukimura O, Kanemitsu N et al (2007) Clinical efficacy of alternative antiandrogen therapy in Japanese men with relapsed prostate cancer after first-line hormonal therapy. Int J Urol 14:128–132
Nishimura K, Arichi N, Tokugawa S et al (2007) Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer. Int J Urol 14:264–267
Yasui M, Uemura K, Yoneyama S et al (2016) Predictors of poor response to secondary alternative antiandrogen therapy with flutamide in metastatic castration-resistant prostate cancer. Jpn J Clin Oncol 46:1042–1046
Akaza H, Hinotsu S, Usami M et al (2009) Combined androgen blockade with bicalutamide for advanced prostate cancer. Cancer 115:3437–3445
Kwak C, Jeong SJ, Park MS et al (2002) Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol 168:995–1000
Altwein JE, Schmidt A (2002) Prostate-specific antigen dynamics predict risk of progression in advanced prostate cancer treated with bicalutamide plus castration. Urol Int 68:220–225
Benaim EA, Pace CM, Lam PM et al (2002) Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer. Urology 59:73–78
Morote J, Trilla E, Esquena S et al (2004) Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer. Int J Cancer 108:877–881
Park SC, Rim JS, Choi HY et al (2009) Failing to achieve a nadir prostate-specific antigen after combined androgen blockade: predictive factors. Int J Urol 16:670–675
Sim HG, Lau WK, Cheng CW et al (2004) Predictors of androgen independence in metastatic prostate cancer. BJU Int 93:1221–1224
Teoh JY, Tsu JH, Yuen SK et al (2017) Survival outcomes of Chinese metastatic prostate cancer patients following primary androgen deprivation therapy in relation to prostate-specific antigen nadir level. Asia Pac J Clin Oncol 13:e65–e71
Tomioka A, Tanaka N, Yoshikawa M et al (2014) Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer. BMC Urol 14:33
Sasaki T, Ohnishi T, Hoshina A (2011) Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis. Prostate Cancer Prostatic Dis 14:248–252
Huang SP, Bao BY, Wu MT et al (2011) Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy. Prostate 71:1189–1197
Hamano I, Hatakeyama S, Narita S et al (2019) Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer. World J Urol. https://doi.org/10.1007/s00345-019-02664-3
Teoh JY, Tsu JH, Yuen SK et al (2015) Prognostic significance of time to prostate-specific antigen (PSA) nadir and its relationship to survival beyond time to PSA nadir for prostate cancer patients with bone metastases after primary androgen deprivation therapy. Ann Surg Oncol 22:1385–1391
Teoh JY, Tsu JH, Yuen SK et al (2017) Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy. Asian J Androl 19:98–102
Choueiri TK, Xie W, D’Amico AV et al (2009) Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer 115:981–987
Acknowledgements
We are grateful to R. Kanaoka, Y. Kohada, T. Babasaki, S. Ohara, and H. Iwamoto for their assistance with data collection. We would like to thank Editage (www.editage.jp) for English language editing.
Funding
This study was not funded by a grant.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All the procedures performed in the study were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments. For this type of study, formal consent is not required.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Fukuoka, K., Teishima, J., Nagamatsu, H. et al. Predictors of poor response to first-generation anti-androgens as criteria for alternate treatments for patients with non-metastatic castration-resistant prostate cancer. Int Urol Nephrol 52, 77–85 (2020). https://doi.org/10.1007/s11255-019-02281-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-019-02281-4